Want to join the conversation?
$MRK announced results from two Phase 3 studies evaluating MK-1293, its investigational, follow-on biologic insulin glargine candidate for treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved primary endpoint by demonstrating non-inferiority in change from baseline A1C and similar safety to Lantus.
I haven’t seen a drop in banks like this in a long time. Looks like $WFC is still facing pressures from its sales practices scandal..!!
Helping President-elect's America first focus, $WMT set to create 10,000 retail jobs in the US in 2017.
Looks like Trump has his eyes on the $MON and Bayer merger next. He had a meeting with the CEOs and apparently got job promises from them.